Festo Ruling May Have Broad Implications In Hatch/Waxman Reform Debate
This article was originally published in The Tan Sheet
Executive Summary
The Supreme Court's decision in the Festo case paves the way for continued debate on Hatch/Waxman patent reform, but could be a blow to generic drug firms
You may also be interested in...
Hatch/Waxman Reform Should Await Pending Supreme Court Decision – Hatch
Congress should wait for an upcoming Supreme Court ruling on the Doctrine of Equivalents before beginning serious work on re-drafting the Hatch/Waxman Act, Sen. Orrin Hatch (R-Utah) said
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands